Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders.
about
A review of malaria vaccine clinical projects based on the WHO rainbow tableImmunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activityStructural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230.A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice.A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses.Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.Particle-based platforms for malaria vaccines.Functional evaluation of malaria Pfs25 DNA vaccine by in vivo electroporation in olive baboonsAn engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding siteApproaches to malaria vaccine development using the retrospectroscope.Enhanced antibody responses to Plasmodium falciparum Pfs28 induced in mice by conjugation to ExoProtein A of Pseudomonas aeruginosa with an improved procedure.Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection.Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults
P2860
Q21034112-BFCF7A1B-F81B-4B1E-8AAB-12422F6DE87BQ28484081-1421E817-943B-4D0A-A326-6C7868919911Q28740771-3575B31C-AF23-4480-9278-06C01B1F0511Q30390705-B75443ED-0620-494E-8D47-CD5BE2AB4A10Q35048518-66CF13DA-074E-4FB2-B3D5-998D9BF604B7Q35887438-2E603113-6FAE-4014-8F9A-DD25DA8F95BFQ36165265-E4847C41-3F08-4C42-80F4-FF554661AC3CQ36396040-657CFF72-DC81-4197-8467-33E378C01FA1Q36941152-1A26D0AC-19DA-4143-84E3-49B14E048198Q37069430-148214D9-DF5C-4FC6-B9FA-8BA0CA66BAB4Q37274832-A8842283-F50D-4D99-BFD9-9BECD65F2759Q37386668-7144286C-1F05-420C-A87F-B129C62ED08CQ37451046-C2EC3F58-45D7-4F92-9686-9CBB83FB4B56Q56342219-305C89B9-5ABE-45A2-976F-EC48D9CC86E2
P2860
Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Addition of CpG ODN to recombi ...... ases the number of responders.
@ast
Addition of CpG ODN to recombi ...... ases the number of responders.
@en
type
label
Addition of CpG ODN to recombi ...... ases the number of responders.
@ast
Addition of CpG ODN to recombi ...... ases the number of responders.
@en
prefLabel
Addition of CpG ODN to recombi ...... ases the number of responders.
@ast
Addition of CpG ODN to recombi ...... ases the number of responders.
@en
P2093
P2860
P1433
P1476
Addition of CpG ODN to recombi ...... ases the number of responders.
@en
P2093
Ababacar Diouf
Allan Saul
David L Narum
Gregory E D Mullen
Guanhong Song
Kelly M Rausch
Lynn Lambert
Olga Muratova
P2860
P304
P356
10.1016/J.VACCINE.2008.03.005
P407
P577
2008-03-27T00:00:00Z